Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EM1C
|
|||
| Former ID |
DIB019124
|
|||
| Drug Name |
Chk2 inhibitor II
|
|||
| Synonyms |
BML-277; 516480-79-8; Chk2 Inhibitor II; Chk2 Inhibitor II hydrate; CHEMBL179583; 2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide; C20H14ClN3O2; 2-[4-(4-Chlorophenoxy)phenyl]-1h-Benzimidazole-6-Carboxamide; 2-[4-(4-chlorophenoxy)phenyl]-1H-1,3-benzodiazole-6-carboxamide; 2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate; 2-arylbenzimidazole; 4a9r; MLS006010751; GTPL5954; BML277; SCHEMBL1723139; CTK8E8283; BDBM34064; DTXSID40433479; MolPort-039-139-575; HMS3229E12; ZINC3815901; EX-A1077; BCP09077
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H14ClN3O2
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)N)OC4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)
|
|||
| InChIKey |
UXGJAOIJSROTTN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 516480-79-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14946094, 24724438, 26758462, 29217525, 46065591, 53800940, 75566488, 85301072, 91146360, 99302680, 103439921, 104219750, 139865336, 139865341, 144221240, 162248071, 163123195, 163688374, 170484625, 175607470, 178102577, 179694520, 204378863, 208265147, 210275017, 210280655, 223704974, 227904993, 243086193, 246265614, 252215134, 252477940
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase Chk2 (RAD53) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell cycle | |||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Pathway Interaction Database | ATM pathway | |||
| FOXM1 transcription factor network | ||||
| p53 pathway | ||||
| PLK3 signaling events | ||||
| Reactome | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
| G2/M DNA damage checkpoint | ||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | ||||
| WikiPathways | DNA Damage Response | |||
| ATM Signaling Pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5954). | |||
| REF 2 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.